new version V2017

All mechanism

     

TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetic kidney disease

amlodipine
IDNT (amlodipine vs PBO), 2001amlodipineplacebo Low risk of bias Negative
finerenone
FIDELIO-DKD ongoing finerenoneplacebo - NCT02540993
FIGARO-DKD ongoing finerenoneplacebo - NCT02545049
irbesartan
IDNT (irbesartan vs amlodipine), 2001irbesartanamlodipine Low risk of bias Suggesting
IPDM (150mg), 2001irbesartanplacebo Exploratory Suggesting
IDNT (irbesartan vs pbo), 2001irbesartanplacebo Low risk of bias Suggesting
losartan
RENAAL, 2001losartanplacebo Low risk of bias Suggesting
olmesartan
ORIENTolmesartanplaceboNegativeNCT00141453
ramipril
DIABHYCAR, 2004ramiprilplacebo Low risk of bias Negative

heart failure with preserved LVEF

candesartan
CHARM preserved, 2003candesartanplacebo Low risk of bias -
irbesartan
I-PRESERVE (McMurray), 2008ibesartanplacebo Low risk of bias NegativeNCT00095238
perindopril
PEP CHF, 2006perindoprilplacebo Low risk of bias Negative

melanoma

Interferon alpha
EORTC18871/DKG 80-1 (Kleeberg), 2004rIFN alpha-2bobservationadjuvantNegative
EORTC18952 (Eggermont), 2005ID IFN alpha-2b (I M)observationadjuvantNegative
EORTC18991 (Eggermont), 2008PEG IFN alpha-2b (I M)observationadjuvantSuggesting
Nordic IFN Trial, 2011ID IFN alpha-2b (I M)observationadjuvantSuggesting
ipilimumab
EORTC 18071 (Eggermont), 2015ipilimumabplaceboadjuvant Low risk of bias Conclusive NCT00636168
nivolumab
CheckMate 238, 2017nivolumabipilimumabadjuvant Low risk of bias ConclusiveNCT02388906
pembrolizumab
KEYNOTE-054, 2018pembrolizumabplaceboadjuvant Low risk of bias Conclusive NCT02362594
trametinib + dabrafenib
COMBI-AD, 2017trametinib and dabrafenibplaceboadjuvantSuggestingNCT01682083
COMBI neo, 2018trametinib and dabrafenib SOCadjuvant - NCT02231775
vemurafenib
BRIM 8, 2018vemurafenibplaceboadjuvantSuggestingNCT01667419

obesity and overweight

Bupropion
Anderson, 2002Bupropionplacebo -
Croft, 2002Bupropionplacebo -
Jain, 2002Bupropionplacebo -
liraglutide
Astrup (NN8022-1807 ), 2009liraglutideplacebo - NCT00422058
lorcaserin
BLOOM-DM (10mg bid)lorcaserinplacebo - NCT00603291
BLOSSOM (10mg bid), 2009lorcaserinplacebo - NCT00603902
BLOOM, 2010lorcaserinplacebo - NCT00395135
orlistat
Hollander, 1998Orlistatplacebo -
Sjostrom, 1998Orlistatplacebo -
Davidson, 1999Orlistatplacebo -
Hill, 1999Orlistatplacebo -
Micic, 1999Orlistatplacebo -
Vidgren, 1999Orlistatplacebo -
Hauptman, 2000Orlistatplacebo -
Karhunen, 2000Orlistatplacebo -
Lindgarde, 2000Orlistatplacebo -
Rossner, 2000Orlistatplacebo -
Broom,, 2001Orlistatplacebo -
Deerochanawong,, 2001Orlistatplacebo -
Gotfredsen, 2001Orlistatplacebo -
Muls, 2001Orlistatplacebo -
Reaven, 2001Orlistatplacebo -
Rissanen, 2001Orlistatplacebo -
Shi Yi, 2001Orlistatplacebo -
Bakris, 2002Orlistatplacebo -
Broom, 2002Orlistatplacebo -
Hanefeld, 2002Orlistatplacebo -
Kelley, 2002Orlistatplacebo -
Miles, 2002Orlistatplacebo -
Naumov, 2002Orlistatplacebo -
Rosenfalck, 2002Orlistatplacebo -
Derosa, 2003Orlistatplacebo -
Halpern, 2003Orlistatplacebo -
Lucas, 2003Orlistatplacebo -
Krempf, 2005Orlistatplacebo -
phentermine and topiramate
CONQUER (mid-dose) (OB 303)PHEN/TPM mid-doseplacebo - NCT00553787
OB 301 (mid-dose)PHEN/TPM mid-doseplacebo -
OB 302 (low-dose)PHEN/TPM low-doseplacebo -
CONQUER (high-dose) (OB 303)PHEN/TPM high doseplacebo - NCT00553787
OB 302 (high-dose)PHEN/TPM high doseplacebo -
OB 301 (high-dose)PHEN/TPM high doseplacebo -
Sibutramine
McMahon, 2000Sibutramineplacebo -
Smith, 2001Sibutramineplacebo -
McMahon, 2002Sibutramineplacebo -
SCOUT, 2010sibutramineplacebo Low risk of bias - NCT00234832
topiramate
Bray, 2003Topiramateplacebo -
Caterson, 2003Topiramateplacebo -
Pud’homme, 2003Topiramateplacebo -
Rissanen, 2003Topiramateplacebo -
Stenlof, 2003Topiramateplacebo -
Tonstad, 2003Topiramateplacebo -